Melanoma Clinical Trials in San Antonio

Showing 61-80 of 108 trials

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

NCT03602079

Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity.

HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more

Klus Pharma Inc.49 participantsStarted Jul 2018

Sarasota, Florida, United States • Boston, Massachusetts, United States • Detroit, Michigan, United States +7 more locations

COMPLETEDPHASE2< 1 mile

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

NCT03679767

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.

Metastatic Non-small Cell Lung CancerLocally Advanced Urothelial CancerMetastatic Urothelial Cancer+4 more

Incyte Corporation121 participantsStarted Jan 2019

Fresno, California, United States • Fresno, California, United States • San Marcos, California, United States +49 more locations

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Melanoma Trials in Other Cities

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Safety Study of SEA-CD40 in Cancer Patients

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Safety Study of MGA271 in Refractory Cancer

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Other Conditions in San Antonio